FCMI
LOXO

Foresite Capital Management III’s Loxo Oncology, Inc LOXO Stock Holding History

Foresite Capital Management III’s Portfolio LOXO Stock Details LOXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-50,000
Closed -$4.61M – 21
2017
Q3 		$4.61M Sell
50,000
-62,500
-56% -$4.86M 1.27% 16
2017
Q2 		$9.02M Buy
112,500
+12,500
+13% +$693K 2.95% 10
2017
Q1 		$4.21M Buy
+100,000
New +$4.12M 1.62% 13

Other funds holding LOXO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Foresite Capital Management III's LOXO Position: Q4 2017 in Review

Foresite Capital Management III sold out of Loxo Oncology, Inc (LOXO) in Q4 2017, closing a stake of 50,000 shares — an estimated $4.61M sold.

Foresite Capital Management III first reported a position in LOXO in Q1 2017 and held it in 3 quarters. The position peaked at $9.02M in Q2 2017. 141 funds tracked by Wall St. Rank hold LOXO as of Q4 2017.

  • Foresite Capital Management III reported no remaining Loxo Oncology, Inc position as of Q4 2017 after selling out during the quarter.
  • Foresite Capital Management III sold 50,000 Loxo Oncology, Inc shares in Q4 2017, an estimated $4.61M.
  • Foresite Capital Management III first reported a position in Loxo Oncology, Inc in Q1 2017 and held it in 3 quarters.
  • Foresite Capital Management III's Loxo Oncology, Inc position peaked at $9.02M in Q2 2017.
  • 141 funds tracked by Wall St. Rank held Loxo Oncology, Inc as of Q4 2017.

Based on Foresite Capital Management III's 13F filing for Q4 2017, filed 13 Feb 2018.